Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,405 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04086485RecruitingPhase 1/Phase 2
Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Bethesda, MarylandAges 18–100 - NCT04090034Recruiting
PRRT for advanced neuroendocrine tumors
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
Dallas, TexasAges 18 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Los Angeles, CaliforniaAges Up to 25 years - NCT04099797RecruitingPhase 1
CAR T therapy for certain GD2 brain tumors
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
Houston, TexasAges 1–25 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT04145622RecruitingPhase 1/Phase 2
Ifinatamab deruxtecan for advanced hard-to-treat solid cancers
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
Los Angeles, CaliforniaAges 18 years+ - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT04166006RecruitingPhase 2
Vaccine made from your tumor cells after surgery for rare cancers
This trial tests a personalized vaccine made from your own tumor material, aiming to lower the chance cancer returns after surgery. It is for people whose rare cancers have been removed completely and who have no standard treatment available after surgery.
Meldola, FCAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT04308330RecruitingPhase 1
Vorinostat plus chemotherapy for advanced tumors in brain
This Phase 1 trial studies how safe and tolerable vorinostat is when combined with chemotherapy for cancers that have come back or are hard to treat, including tumors in the brain or spinal cord. It may help doctors find a better way to treat advanced solid tumors and CNS (brain/spinal cord) cancers.
Valhalla, New YorkAges 1–30 - NCT04354064Recruiting
Blood DNA test to see early treatment response in solid tumors
This study looks at circulating tumor DNA, which is tiny bits of DNA found in blood, to help assess how solid tumors are responding early. It uses blood samples from healthy adults who are willing to donate.
St Louis, MissouriAges 18 years+ - NCT04403867Recruiting
Study of tiny cancer spread found in sentinel lymph nodes
This trial studies whether very small deposits of cancer (called micrometastasis or isolated tumor cells) are found in sentinel lymph nodes in early endometrial or cervical cancer. The goal is to better understand what these findings may mean for cancer spread and treatment planning.
MilanAges 18 years+ - NCT04464122Recruiting
Testing blood markers to diagnose and gauge early response in NEN
This trial studies whether specific blood “biomarkers” can help confirm a type of cancer called NEN (neuroendocrine neoplasm) and show whether treatment is working early. It may help doctors start or adjust treatment sooner, especially for cancers that are advanced or have spread.
Rome, ItalyAges 18–80 - NCT04520932Recruiting
Radiofrequency treatment for small nonfunctioning pancreatic tumors
This trial tests whether heating (radiofrequency) treatment guided by a special ultrasound scope can control small pancreatic neuroendocrine tumors. It may help patients whose tumors are very small and do not release hormones.
MarseilleAges 18–80 - NCT04537936Recruiting
Spanish psychotherapy support for Latino adults with advanced cancer
This study tests a Spanish-language psychotherapy approach to help Latino adults with stage III or IV solid tumors (advanced cancer). It aims to see how well the therapy reduces distress and how patients and clinicians feel about it.
New York, New YorkAges 18 years+ - NCT04557969Recruiting
Surgery and tumor testing in gastrointestinal stromal tumors (GIST)
This study looks at how surgery for gastrointestinal stromal tumors (GIST) works, and collects tumor samples to study them under the microscope and by DNA testing. Your results may help researchers better predict tumor behavior and guide future treatment.
Bethesda, MarylandAges 6 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04677205Recruiting
Tumor-to-lymph-node study after lung cancer surgery
This study looks at molecular (biologic) signals in the tumor and nearby lymph nodes after curative surgery for stage IIIA lung cancer. It may help doctors better understand the disease and improve future treatment planning.
BordeauxAges 18 years+ - NCT04732065RecruitingPhase 1
ONC206 for certain brain tumors in children and young adults
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
San Francisco, CaliforniaAges 2–21 - NCT04770207RecruitingPhase 2
Injecting a cancer drug mixture directly into tumors
This Phase 2 study tests a treatment where drug-loaded tiny beads are injected into a solid tumor, using more than one medicine. It may help people with advanced solid cancers by delivering the drugs right at the tumor site.
Guangzhou, GuangdongAges 18–99 - NCT04804007RecruitingPhase 2
Etoposide or watchful waiting after high-dose chemo
This phase 2 study looks at whether taking oral etoposide after high-dose chemotherapy helps people with a certain type of testicular or ovarian cancer avoid relapse. If you qualify, you may be assigned to take the medicine or simply be monitored without additional treatment.
Indianapolis, IndianaAges 18 years+ - NCT04842812RecruitingPhase 1
Personalized immune cell therapy for advanced solid tumors
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
GuangzhouAges 18–85 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT04925609RecruitingPhase 1/Phase 2
Brigatinib for young people with ALK-positive cancer
This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.
ParisAges 1–25
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,405 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.